Home Business News Possibly the two best pharma stocks with the potential to rise in prices in 2024

Possibly the two best pharma stocks with the potential to rise in prices in 2024

3rd May 24 10:45 am

The pharmaceutical industry is different from other industries, and because of this, finding and investing in the right pharma stocks can be more tricky than expected.

Although it can be tricky and, in many cases, more volatile, the pharma industry is one of the most profitable industries.

  • Pharma stocks are generally more tricky to navigate and often require advanced knowledge of sectors like biology and chemistry.
  • Deciphera Pharmaceuticals offers diverse drugs and pharmaceutical products to help cancer patients manage the disease.
  • ANI Pharmaceuticals produces drugs and pharmaceutical products across several use cases, such as hormonal treatment and steroids.

Even though pharma stocks have not been in the news headlines recently, the constant demand for health-related products and services ensures that they are a safe bet. When you also factor in the growth of biotech and biotech use cases, it is evident that pharma stocks will be in high demand soon.

Financial Analyst at Trading.biz Joel Lim has identified two of the best pharmaceutical stocks with the most potential for a price increase in the market. Deciphera Pharmaceuticals and ANI Pharmaceuticals are two undervalued pharmaceutical stocks you should invest in as soon as possible for massive returns.

Deciphera Pharmaceuticals (DCPH)

Deciphera Pharmaceuticals is an emerging giant in the biopharmaceutical space. The company is one of the few that have discovered, developed, and distributed new medicine to improve the lives and well-being of cancer patients.

A recent report shows that a growing number of hedge funds hold a stake in the company, around 24 out of the 933 tracked by Insider Monkey. It is one of the growing healthcare companies exhibiting a solid share price rating, and analysts claim that the stock has shown a 54% increase over the last six months.

Joel Lim notes, “As the demand for biomedicine increases, the industry will record massive growth, which will also reflect in its stocks. Deciphera Pharmaceuticals (DCPH) is one such stock, and it holds an advantage over others thanks to its use case.”

ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals develops and distributes prescription medication for several cases, such as central nervous system (CNS) disorders, gastrointestinal, cancer, hormonal treatment, and lots more. Thanks to its wide range of services, the company is emerging as a force to contend with in the biopharmaceutical space. Interest in biomedicine is at an all-time high, and this is likely to reflect in the market.

Analysts claim that ANI Pharmaceuticals has performed well over the last 12 months, recording a 41% gain in the market. A growing number of hedge funds are also taking an interest in the company, evidenced by the 19 shareholders in the firm, according to Insider Monkey.

Joel Lim notes, “ANI Pharmaceuticals stock offers the best of both worlds to investors as it has a diverse portfolio of treatments and prescriptions, making it a high-value stock that could record a price increase sooner rather than later.”

Leave a Comment

You may also like


Sign up to our daily news alerts

[ms-form id=1]